The Oncology Institute, Inc. $TOI Shares Acquired by FourWorld Capital Management LLC

FourWorld Capital Management LLC increased its position in shares of The Oncology Institute, Inc. (NASDAQ:TOI) by 30.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 499,196 shares of the company’s stock after acquiring an additional 116,496 shares during the quarter. Oncology Institute makes up about 0.8% of FourWorld Capital Management LLC’s portfolio, making the stock its 13th biggest holding. FourWorld Capital Management LLC owned approximately 0.51% of Oncology Institute worth $1,533,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Kestra Advisory Services LLC acquired a new position in Oncology Institute in the 4th quarter valued at about $31,000. Pekin Hardy Strauss Inc. purchased a new stake in shares of Oncology Institute in the 4th quarter valued at approximately $36,000. R Squared Ltd acquired a new stake in shares of Oncology Institute during the 4th quarter worth approximately $41,000. Prelude Capital Management LLC acquired a new stake in shares of Oncology Institute during the 3rd quarter worth approximately $41,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of Oncology Institute by 141.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,119 shares of the company’s stock worth $42,000 after buying an additional 7,091 shares during the last quarter. 36.86% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TOI has been the topic of a number of recent research reports. Needham & Company LLC upped their target price on shares of Oncology Institute from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Wednesday, June 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncology Institute in a research note on Friday, July 17th. Lake Street Capital initiated coverage on shares of Oncology Institute in a report on Monday, July 6th. They set a “buy” rating and a $10.00 price target for the company. Finally, BTIG Research increased their price objective on shares of Oncology Institute from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Oncology Institute currently has a consensus rating of “Moderate Buy” and an average price target of $8.50.

Insider Buying and Selling

In related news, major shareholder Jorey Chernett bought 33,500 shares of the stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average price of $4.07 per share, for a total transaction of $136,345.00. Following the acquisition, the insider owned 10,567,858 shares in the company, valued at approximately $43,011,182.06. This represents a 0.32% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Yale Podnos sold 23,451 shares of the stock in a transaction on Monday, June 8th. The shares were sold at an average price of $5.38, for a total transaction of $126,166.38. Following the completion of the transaction, the insider directly owned 259,527 shares in the company, valued at $1,396,255.26. This trade represents a 8.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders purchased 113,500 shares of company stock valued at $514,405 over the last ninety days. 4.40% of the stock is currently owned by corporate insiders.

Oncology Institute Price Performance

Shares of NASDAQ TOI opened at $4.98 on Monday. The company has a market capitalization of $492.22 million, a price-to-earnings ratio of -13.46 and a beta of 0.36. The business has a 50-day moving average of $5.11 and a two-hundred day moving average of $3.88. The Oncology Institute, Inc. has a 1 year low of $2.32 and a 1 year high of $6.67.

Oncology Institute (NASDAQ:TOI) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.05. The business had revenue of $147.44 million during the quarter, compared to analysts’ expectations of $142.10 million. As a group, equities research analysts expect that The Oncology Institute, Inc. will post -0.18 earnings per share for the current year.

Oncology Institute Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.